<!DOCTYPE html>
<html>
<head>
    <title>TAK-981 vs DMSO TOBIAS Analysis</title>
    <style>
        body { font-family: Arial, sans-serif; margin: 40px; }
        .header { background-color: #f0f8ff; padding: 20px; border-radius: 10px; }
        .section { margin: 20px 0; }
        .track-desc { background-color: #f9f9f9; padding: 15px; margin: 10px 0; border-radius: 5px; }
        .stats { background-color: #fff3cd; padding: 15px; border-radius: 5px; }
        table { border-collapse: collapse; width: 100%; }
        th, td { border: 1px solid #ddd; padding: 8px; text-align: left; }
        th { background-color: #f2f2f2; }
    </style>
</head>
<body>
    <div class="header">
        <h1>TAK-981 SUMOylation Inhibitor vs DMSO Control</h1>
        <h2>ATAC-seq Footprinting Analysis with TOBIAS</h2>
        <p><strong>Analysis Date:</strong> Tue Jul 15 13:33:26 CDT 2025</p>
    </div>
    
    <div class="section">
        <h3>üß¨ Experimental Design</h3>
        <table>
            <tr><th>Parameter</th><th>Value</th></tr>
            <tr><td>Treatment</td><td>TAK-981 (SUMOylation inhibitor) vs DMSO control</td></tr>
            <tr><td>Biological Replicates</td><td>4 per condition (8 total)</td></tr>
            <tr><td>Method</td><td>ATAC-seq followed by TOBIAS footprinting</td></tr>
            <tr><td>Genome Assembly</td><td>Mouse GRCm39/mm39</td></tr>
            <tr><td>Cell Lines</td><td>M408, M1196, M1199, M1332</td></tr>
        </table>
    </div>
    
    <div class="section">
        <h3>üìä Track Types Available</h3>
        
        <div class="track-desc">
            <h4>üî¥ Corrected ATAC-seq Signal (Primary)</h4>
            <p><strong>Most Important Tracks:</strong> Bias-corrected chromatin accessibility signal</p>
            <ul>
                <li>Blue tracks: DMSO control samples</li>
                <li>Red tracks: TAK-981 treated samples</li>
                <li>Shows where chromatin is accessible to transcription factors</li>
                <li>Higher signal = more accessible chromatin</li>
            </ul>
        </div>
        
        <div class="track-desc">
            <h4>üë£ Footprint Scores</h4>
            <p><strong>TF Binding Predictions:</strong> TOBIAS-calculated footprint scores</p>
            <ul>
                <li>Light blue: DMSO footprints</li>
                <li>Orange: TAK-981 footprints</li>
                <li>Higher scores = stronger predicted TF binding</li>
                <li>Shows precise locations where TFs are likely bound</li>
            </ul>
        </div>
        
        <div class="track-desc">
            <h4>üìç Peak Annotations</h4>
            <p><strong>Accessible Regions:</strong> ATAC-seq peak calls</p>
            <ul>
                <li>Gray: All merged peaks across samples</li>
                <li>Light gray: Unique peaks</li>
                <li>Defines regions of chromatin accessibility</li>
            </ul>
        </div>
        
        <div class="track-desc">
            <h4>üîç Raw ATAC-seq (Hidden by Default)</h4>
            <p><strong>Comparison Data:</strong> Uncorrected ATAC signal</p>
            <ul>
                <li>Shows raw data before bias correction</li>
                <li>Useful for comparing correction effects</li>
                <li>Hidden by default - activate to compare</li>
            </ul>
        </div>
    </div>
    
    <div class="section stats">
        <h3>üî¨ Key Biological Findings</h3>
        <ul>
            <li><strong>1,646 transcription factors analyzed</strong> across the genome</li>
            <li><strong>630 TFs show decreased binding</strong> (38.3%) after TAK-981</li>
            <li><strong>697 TFs show increased binding</strong> (42.3%) after TAK-981</li>
            <li><strong>AP-1 family most affected:</strong> JUNB, FOS, FOSL1 dramatically decreased</li>
            <li><strong>Effect range:</strong> -18% to +43% binding change</li>
            <li><strong>Statistical significance:</strong> All changes p < 1e-169</li>
        </ul>
    </div>
    
    <div class="section">
        <h3>üéØ Suggested Viewing Regions</h3>
        <table>
            <tr><th>Gene/Region</th><th>Coordinates (mm39)</th><th>Expected Result</th></tr>
            <tr><td>Fos (AP-1 component)</td><td>chr12:85,474,000-85,479,000</td><td>Decreased TAK signal</td></tr>
            <tr><td>Jun (AP-1 component)</td><td>chr4:148,950,000-148,957,000</td><td>Decreased TAK signal</td></tr>
            <tr><td>Junb (AP-1 component)</td><td>chr8:84,977,000-84,980,000</td><td>Decreased TAK signal</td></tr>
            <tr><td>Smad2 (TGF-Œ≤ pathway)</td><td>chr18:76,290,000-76,380,000</td><td>Decreased TAK signal</td></tr>
        </table>
    </div>
    
    <div class="section">
        <h3>üî¨ Analysis Pipeline</h3>
        <ol>
            <li><strong>ATACorrect:</strong> Bias correction of ATAC-seq signal</li>
            <li><strong>FootprintScores:</strong> Prediction of TF binding sites</li>
            <li><strong>BINDetect:</strong> Differential binding analysis across 1,646 TFs</li>
            <li><strong>Statistical Testing:</strong> Pairwise comparisons (16 per TF)</li>
        </ol>
        
        <p><strong>Reference:</strong> Bentsen, M., Goymann, P., Schultheis, H. et al. TOBIAS: analysis of transcription factor binding and chromatin accessibility. Nat Commun 11, 5893 (2020).</p>
    </div>
    
    <div class="section">
        <h3>üìß Contact Information</h3>
        <p>For questions about this analysis, contact the Martin Lab.</p>
    </div>
</body>
</html>
